1-4 of 4
Samina Shazi
Close
Sort by
Journal Articles

Optimaization of Imatinib Therapy by Combination. 5 Year Survival and Response Results of the Pilot Phase of the Randomized German CML STUDY IV.

Nadine Pletsch, Susanne Saussele, Michael Lauseker, Armin Leitner, Susanne Jung-Munkwitz, Samina Shazi, Claudia Haferlach, Brigitte Schlegelberger, Martin C Müller, Thomas Schenk, Susanne Schnittger, Markus Pfirrmann, Gerhard Ehninger, Thomas Fischer, Dieter K. Hossfeld, Hans-Jochem Kolb, Stefan W Krause, Christoph Nerl, Hans Pralle, Alois Gratwohl, Andreas Tobler, Hermann Heimpel, Leopold Balleisen, Hermann Einsele, Anthony D. Ho, Christine Falge, Mathias Hänel, Michael Pfreundschuh, Lothar Kanz, Frank Stegelmann, Claus-Henning Köhne, Stephan Kremers, Karsten Spiekermann, Wolfgang E Berdel, Cornelius F. Waller, Martin Bentz, Joerg Hasford, Andreas Hochhaus, Rüdiger Hehlmann, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 862.
https://doi.org/10.1182/blood.V114.22.862.862
Published: 2009
Journal Articles

Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.

Rudiger Hehlmann, Susanne Jung-Munkwitz, Michael Lauseker, Armin Leitner, Nadine Pletsch, Samina Shazi, Martin C. Müller, Claudia Haferlach, Brigitte Schlegelberger, Susanne Schnittger, PhD, Cornelius F. Waller, Andreas Neubauer, Lothar Kanz, MD, Mathias Hänel, Jiri Mayer, Frank Stegelmann, Roland Fuchs, Wolfgang E. Berdel, Leopold Balleisen, Markus Pfirrmann, Gerhard Ehninger, Thomas Fischer, Dieter K. Hossfeld, Hans- Jochem Kolb, Stefan W. Krause, Christoph Nerl, Hans Pralle, Alois Gratwohl, Andreas Tobler, Hermann Heimpel, Joerg Hasford, Andreas Hochhaus, Susanne Saussele, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 339.
https://doi.org/10.1182/blood.V114.22.339.339
Published: 2009
Journal Articles

Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV.

Susanne Saussele, Michael Lauseker, Markus Pfirrmann, Armin Leitner, Nadine Pletsch, Frank Stegelmann, Anthony D Ho, Günter Schlimok, Albrecht Lindemann, Dietrich W Beelen, Alois Gratwohl, Mathias Hänel, Claudia Haferlach, Brigitte Schlegelberger, Martin C Müller, Philipp Erben, Susanne Schnittger, Susanne Jung-Munkwitz, Samina Shazi, Joerg Hasford, Andreas Hochhaus, Rüdiger Hehlmann, The German CML Study Group
Journal: Blood
Blood (2009) 114 (22): 3287.
https://doi.org/10.1182/blood.V114.22.3287.3287
Published: 2009
Journal Articles

Weekend Drug Holiday of Dasatinib in CML Patients Not Tolerating Standard Dosing Regimens. Reducing Toxicity with Maintained Disease Control.

Paul La Rosee, MD, Armin Leitner, MD, Philippe Martiat, MD, Thomas Klag, MD, Samina Shazi, MD, Anne Treschl, MD, Martin C Müller, MD, Thomas Schenk, MD, Benjamin Hanfstein, Andreas Hochhaus, MD
Journal: Blood
Blood (2009) 114 (22): 1119.
https://doi.org/10.1182/blood.V114.22.1119.1119
Published: 2009